Notes
National Health Service
Reference
Takeda. NICE Recommends Takhzyro(Rm) (Lanadelumab) for the Treatment of People Living With Rare Debilitating Genetic Disorder. Media Release : 18 Sep 2019. Available from: URL: http://www.takeda.com
Rights and permissions
About this article
Cite this article
NICE recommends lanadelumab. PharmacoEcon Outcomes News 838, 35 (2019). https://doi.org/10.1007/s40274-019-6280-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6280-0